867 related articles for article (PubMed ID: 30142429)
1. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
2. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF
J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
[TBL] [Abstract][Full Text] [Related]
7. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
[TBL] [Abstract][Full Text] [Related]
8. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
10. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
[TBL] [Abstract][Full Text] [Related]
11. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
[TBL] [Abstract][Full Text] [Related]
12. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
[TBL] [Abstract][Full Text] [Related]
13. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs.
Latham NH; Doyle JS; Palmer AY; Vanhommerig JW; Agius P; Goutzamanis S; Li Z; Pedrana A; Gottfredsson M; Bouscaillou J; Luhmann N; Mazhnaya A; Altice FL; Saeed S; Klein M; Falade-Nwulia OO; Aspinall E; Hutchinson S; Hellard ME; Sacks-Davis R
Liver Int; 2019 Dec; 39(12):2244-2260. PubMed ID: 31125496
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
15. A Phylogenetic Analysis of Hepatitis C Virus Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Ganova-Raeva L; Punkova LT; Agyemang L; Sue A; Ramachandran S; Khudyakov Y; Litwin AH
J Infect Dis; 2020 Jul; 222(3):488-498. PubMed ID: 32150621
[TBL] [Abstract][Full Text] [Related]
16. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
17. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
Weir A; McLeod A; Innes H; Valerio H; Aspinall EJ; Goldberg DJ; Barclay ST; Dillon JF; Fox R; Fraser A; Hayes PC; Kennedy N; Mills PR; Stanley AJ; Aitken C; Gunson R; Templeton K; Hunt A; McIntyre P; Hutchinson SJ
Drug Alcohol Depend; 2016 Aug; 165():53-60. PubMed ID: 27268294
[TBL] [Abstract][Full Text] [Related]
19. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
20. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
Berenguer J; Gil-Martin Á; Jarrin I; Montes ML; Domínguez L; Aldámiz-Echevarría T; Téllez MJ; Santos I; Troya J; Losa JE; Serrano R; De Guzmán MT; Calvo MJ; González-García JJ;
AIDS; 2019 Mar; 33(4):685-689. PubMed ID: 30829744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
